Argenica Therapeutics Ltd (AGN) - Cash Flow Conversion Efficiency

Latest as of December 2025: -1.602x

Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has a cash flow conversion efficiency ratio of -1.602x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.51 Million ≈ $-3.90 Million USD) by net assets (AU$3.44 Million ≈ $2.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Argenica Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)

This chart illustrates how Argenica Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Argenica Therapeutics Ltd total liabilities for a breakdown of total debt and financial obligations.

Argenica Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Argenica Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
RPCG Public Company Limited
BK:RPC
-0.007x
Janfusun Fancyworld
TWO:5701
0.066x
Mega Polietilen Kopuk Sanayi ve Ticaret AS
IS:MEGAP
-0.371x
Middle Island Resources Ltd
AU:MDI
-0.200x
MyTech Group Bhd
KLSE:7692
0.081x
Cubex Tubings Limited
NSE:CUBEXTUB
0.005x
Immo Moury SICAF Immobiliere Publique de Droit Belge
BR:IMMOU
0.026x
Torrent Capital Ltd
V:TORR
0.075x

Annual Cash Flow Conversion Efficiency for Argenica Therapeutics Ltd (2019–2024)

The table below shows the annual cash flow conversion efficiency of Argenica Therapeutics Ltd from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Argenica Therapeutics Ltd (AGN) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 AU$7.24 Million
≈ $5.12 Million
AU$-5.70 Million
≈ $-4.04 Million
-0.788x -117.29%
2023-12-31 AU$13.95 Million
≈ $9.87 Million
AU$-5.06 Million
≈ $-3.58 Million
-0.363x +15.74%
2022-12-31 AU$7.67 Million
≈ $5.42 Million
AU$-3.30 Million
≈ $-2.34 Million
-0.430x -6.38%
2021-12-31 AU$8.31 Million
≈ $5.88 Million
AU$-3.36 Million
≈ $-2.38 Million
-0.405x -164.77%
2020-12-31 AU$6.85 Million
≈ $4.84 Million
AU$-1.05 Million
≈ $-740.40K
-0.153x +95.22%
2019-12-31 AU$18.40K
≈ $13.02K
AU$-58.82K
≈ $-41.62K
-3.197x --

About Argenica Therapeutics Ltd

AU:AGN Australia Biotechnology
Market Cap
$15.45 Million
AU$21.84 Million AUD
Market Cap Rank
#25743 Global
#1180 in Australia
Share Price
AU$0.17
Change (1 day)
+0.00%
52-Week Range
AU$0.14 - AU$0.83
All Time High
AU$0.99
About

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more